Precision Immunotherapies for Solid Tumors Built on Functional Biology at the Single-Cell Level
Where conventional discovery tests binders sequentially over months, our TCELERATORTM platform profiles more than 10 million single-cell interactions at once, identifying functional leads in a single experiment.
We further combine this platform with computational engineering and translational immunology into a unified engine to develop more selective and safer therapeutics, starting with next-generation T-cell engagers against both surface and intracellular cancer targets.
Powered by Our Unified Engine
Rather than approaching drug development as a series of disconnected steps, ShennonBio seamlessly integrates target discovery, functional screening of binders, computational optimization, and predictive safety assessment to enable faster iteration and deeper biological insight.
This biology-driven approach is enabled by proprietary human tumor datasets built through an expanding network of academic and clinical collaborators across 15 institutions, and 6,000 square feet of laboratory and office space in San Francisco near UCSF Mission Bay.
Centered around people
We believe that people are the key that drives scientific and organizational successes. We are dedicated to building an environment where everyone thrives. We have a culture of collaboration, ownership, and authenticity. We are proud to have built an interdisciplinary team that embodies this culture.
.png)
Latest News
Shennon Biotechnologies Raises $13M Seed Financing to Accelerate Immunotherapy Target Discovery with Proprietary Single-Cell Functional Screening Platform
Read Article
How a onetime VC came back to science to focus on finding better targets faster against cancer
Read Article
Work with Us to Cure the Incurable
